Background HASPIN, a mitotic kinase for Histone H3, is a promising target for anti-cancer therapy. However, as HASPIN is an atypical kinase with low similarity to eukaryotic protein kinases, development of a HASPIN inhibitor from the conventional pharmacophore of kinase inhibitors would be technically challenging.

中文翻译：

---

一种新型 HASPIN 抑制剂的鉴定及其与 PLK1 抑制剂的协同作用

背景HASPIN 是组蛋白 H3 的有丝分裂激酶，是一种有希望的抗癌治疗靶点。然而，由于 HASPIN 是一种非典型激酶，与真核蛋白激酶的相似性低，因此从激酶抑制剂的常规药效团开发 HASPIN 抑制剂在技术上具有挑战性。